We are pleased to present below all posts archived in 'November, 2014'. If you still can't find what you are looking for, try using the search box.
28 November, 2014: The board is pleased to announce that the further assessment of an additional 20 cases of pancreatic cancer using SysQuant® has recently been completed. The results validate the findings from the first 12 cases that were published earlier this year in PLOS ONE. As well as potential new drug targets, a key outcome of this study is a set of new biomarkers predicting the likelihood and timescale of tumour recurrence after surgery and the ability to match patients to individual drug treatments.
Read the rest of entry »
The new AdvanDx mecA XpressFISH assay, exclusively available in the UK from Alpha Laboratories, is the first and only molecular assay that detects the active resistance gene (mecA) from positive Staphylococcus aureus blood cultures.
The successful development of new platform technology for the rapid point of care (POC) diagnosis of flu and other respiratory conditions has widespread potential for the detection of a wide range of other infectious diseases.
Cardiff, UK – 6 November 2014 – EKF Diagnostics, the global diagnostics company, has announced that senior executives from EKF Molecular Diagnostics including CEO, Andrew Webb, will be present at the Association for Molecular Pathology (AMP) annual meeting on booth 1028, to discuss with delegates the predicted outcomes of its research collaboration with Massachusetts General Hospital (MGH). Under the two year agreement, EKF Molecular will develop high sensitivity assays for the detection of genetic variation in circulating tumour cells (CTCs), using its PointMan™ DNA enrichment technology.
Who are the BIVDA Members
Member Press Releases
Point of Care Directory
News, Policy and Media
BIVDA Press Releases